TEVA PHARMACEUTICAL IND LTD
TEVANYSETrading Snapshot
- Day Range
- $39.49 β $40.62
- 52-Week Range
- $6,160.00 β $12,150.00
- Volume
- $3.48B
- Avg Volume
- $3.45B
- Shares Outstanding
- 1.16B
- Next Earnings
- Dec 8, 2026
Fundamentals Snapshot
- Annual Revenue
- $17.26B
- Last Q Revenue
- $4.14B
- P/E Ratio
- 64.5
- P/S Ratio
- 2.6x
- EPS (TTM)
- $0.60
- Dividend Yield
- β
- Dilution (1yr)
- +3.5%
Why Investors Own TEVA
- βHigh-growth profile β revenue up +34.2% YoY with expanding US Equity exposure.
- βHealthy economics β 36% gross margin and 18% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TEVA PHARMACEUTICAL IND LTD
TEVAAbout TEVA PHARMACEUTICAL IND LTD
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Price Target
βLatest News & Updates
TEVA PHARMACEUTICAL IND LTD tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift TEVA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
TEVA PHARMACEUTICAL IND LTD announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.